Råket, H. K., Ankarfeldt, M. Z., Wang, J. N., Pressler, T.
, Jensen-Fangel, S., Qvist, T., Faurholt-Jepsen, D., Jimenez-Solem, E., Petersen, J., Jensen, C. B. & on behalf of the TransformCF Study Group (2025).
Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: Impact on Hospitalizations and Health Care Resource Utilization in a Universal Health Care Setting.
Pulmonary Therapy,
11(2), 235-247.
https://doi.org/10.1007/s41030-025-00287-1